VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GU 2021 | Using the polygenic risk score for targeted prostate cancer screening

Jana McHugh, MD, of The Institute of Cancer Research, London, UK, gives a brief background of the BARCODE1 (NCT03857477) pilot study, which examines the feasibility of a community-based screening program using polygenic risk score for target screening of men at high risk for prostate cancer. Early results of 18 men who underwent a prostate MRI and biopsy after a high polygenic risk score reported a 38.8% detection rate of prostate cancer. Full rollout of the BARCODE1 study has genotyped 3000 men, 322 of whom ranked in the top 10% of polygenic risk score. 117 men received MRI scans, 18 of whom were biopsied, and 12 cancers were detected and patients were directed towards treatment. Further screening is still ongoing, however results promise possible integration of the polygenic risk score in future screening programs. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Dr Jana McHugh, MD, has received institutional research grants from the European Research Council, the NIRH Biomedical Research Centre at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter